PL3976581T3 - Sole kwasu winowego [2-(3-fluoro-5-metanosulfonylofenoksy)etylo](propylo)aminy - Google Patents
Sole kwasu winowego [2-(3-fluoro-5-metanosulfonylofenoksy)etylo](propylo)aminyInfo
- Publication number
- PL3976581T3 PL3976581T3 PL20725728.8T PL20725728T PL3976581T3 PL 3976581 T3 PL3976581 T3 PL 3976581T3 PL 20725728 T PL20725728 T PL 20725728T PL 3976581 T3 PL3976581 T3 PL 3976581T3
- Authority
- PL
- Poland
- Prior art keywords
- sulfonylphenoxy
- fluoro
- methane
- propyl
- amine
- Prior art date
Links
- OSBPYFBXSLJHCR-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine Chemical class CCCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 OSBPYFBXSLJHCR-UHFFFAOYSA-N 0.000 title 1
- 150000003892 tartrate salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176514 | 2019-05-24 | ||
| EP20166361 | 2020-03-27 | ||
| PCT/EP2020/064046 WO2020239568A1 (en) | 2019-05-24 | 2020-05-20 | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3976581T3 true PL3976581T3 (pl) | 2024-07-01 |
Family
ID=70682855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20725728.8T PL3976581T3 (pl) | 2019-05-24 | 2020-05-20 | Sole kwasu winowego [2-(3-fluoro-5-metanosulfonylofenoksy)etylo](propylo)aminy |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12275694B2 (https=) |
| EP (2) | EP4292653B1 (https=) |
| JP (1) | JP7623958B2 (https=) |
| KR (1) | KR102892833B1 (https=) |
| CN (1) | CN113853369B (https=) |
| AU (1) | AU2020286003B2 (https=) |
| BR (1) | BR112021023563A2 (https=) |
| CA (1) | CA3140805A1 (https=) |
| CL (1) | CL2021003115A1 (https=) |
| CO (1) | CO2021016556A2 (https=) |
| DK (1) | DK3976581T3 (https=) |
| ES (1) | ES2970361T3 (https=) |
| FI (1) | FI3976581T3 (https=) |
| IL (1) | IL288271B2 (https=) |
| JO (1) | JOP20210312A1 (https=) |
| MX (1) | MX2021014271A (https=) |
| PH (1) | PH12021552844A1 (https=) |
| PL (1) | PL3976581T3 (https=) |
| PT (1) | PT3976581T (https=) |
| SG (1) | SG11202112165QA (https=) |
| WO (1) | WO2020239568A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3976581T3 (fi) | 2019-05-24 | 2024-01-31 | Irl 790 Ab | [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat |
| CN116685314A (zh) * | 2020-11-10 | 2023-09-01 | 综合研究实验室瑞典股份公司 | 用于预防或减轻对用于帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺（美多培坦） |
| EP4577201A1 (en) * | 2022-08-24 | 2025-07-02 | Alkem Laboratories Limited | Mesdopetam compositions |
| WO2024062344A1 (en) | 2022-09-21 | 2024-03-28 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts therof |
| GB202312055D0 (en) | 2023-08-07 | 2023-09-20 | Ipsen Biopharm Ltd | Pharmaceutical compositions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51123821A (en) | 1975-04-18 | 1976-10-28 | Nippon Kayaku Co Ltd | An algicide and protective agent |
| US4128574A (en) * | 1976-10-04 | 1978-12-05 | General Electric Company | Method for making organic polycarboxylic acids |
| GB8823405D0 (en) | 1988-10-05 | 1988-11-09 | Erba Carlo Spa | Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines |
| PT707007E (pt) | 1994-10-14 | 2002-06-28 | Merck Patent Gmbh | Derivados amino(tio)eter como agentes activos no snc |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| DOP2001000189A (es) | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| JP2006193494A (ja) | 2005-01-17 | 2006-07-27 | Dainippon Ink & Chem Inc | ４級アンモニウム系化合物を有効成分とする心臓疾患治療剤 |
| KR20080036957A (ko) | 2005-06-23 | 2008-04-29 | 아스트라제네카 아베 | 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체 |
| WO2007063789A1 (ja) | 2005-11-29 | 2007-06-07 | Kissei Pharmaceutical Co., Ltd. | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2007072041A1 (en) | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| NZ570633A (en) * | 2006-02-15 | 2011-12-22 | Ms Science Corp | Flurophenoxy-piperazine derivatives |
| WO2008153958A2 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| EP2271638B1 (en) | 2008-04-29 | 2011-08-31 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| WO2009133109A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| AU2009242092A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| EP2699543B1 (en) | 2011-04-19 | 2016-03-02 | Integrative Research Laboratories Sweden AB | Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| CN117304079A (zh) | 2016-02-08 | 2023-12-29 | 默克专利股份有限公司 | N-(4,5-双甲磺酰基-2-甲基苯甲酰基)胍盐酸盐和n-(4,5-双甲磺酰基-2-甲基苯甲酰基)胍盐的结晶变体 |
| ES2943252T3 (es) | 2017-05-19 | 2023-06-12 | Integrative Res Laboratories Sweden Ab | Fumarato de (+)-3-(2,3-difluorofenil)-3-metoxipirrolidina, un proceso para su preparación y sus usos |
| MX2020001311A (es) * | 2017-08-07 | 2020-03-20 | Suven Life Sciences Ltd | Compuestos de fluoropiperidina como antagonistas del receptor 5-hidroxitriptamina 6 puro. |
| WO2020110128A1 (en) | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| FI3976581T3 (fi) | 2019-05-24 | 2024-01-31 | Irl 790 Ab | [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat |
-
2020
- 2020-05-20 FI FIEP20725728.8T patent/FI3976581T3/fi active
- 2020-05-20 PL PL20725728.8T patent/PL3976581T3/pl unknown
- 2020-05-20 PH PH1/2021/552844A patent/PH12021552844A1/en unknown
- 2020-05-20 US US17/612,902 patent/US12275694B2/en active Active
- 2020-05-20 ES ES20725728T patent/ES2970361T3/es active Active
- 2020-05-20 CA CA3140805A patent/CA3140805A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064046 patent/WO2020239568A1/en not_active Ceased
- 2020-05-20 MX MX2021014271A patent/MX2021014271A/es unknown
- 2020-05-20 EP EP23190702.3A patent/EP4292653B1/en active Active
- 2020-05-20 JP JP2021569359A patent/JP7623958B2/ja active Active
- 2020-05-20 DK DK20725728.8T patent/DK3976581T3/da active
- 2020-05-20 KR KR1020217037818A patent/KR102892833B1/ko active Active
- 2020-05-20 PT PT207257288T patent/PT3976581T/pt unknown
- 2020-05-20 IL IL288271A patent/IL288271B2/en unknown
- 2020-05-20 AU AU2020286003A patent/AU2020286003B2/en active Active
- 2020-05-20 CN CN202080036829.0A patent/CN113853369B/zh active Active
- 2020-05-20 BR BR112021023563A patent/BR112021023563A2/pt unknown
- 2020-05-20 EP EP20725728.8A patent/EP3976581B1/en active Active
- 2020-05-20 SG SG11202112165QA patent/SG11202112165QA/en unknown
-
2021
- 2021-11-24 CL CL2021003115A patent/CL2021003115A1/es unknown
- 2021-11-24 JO JOP/2021/0312A patent/JOP20210312A1/ar unknown
- 2021-12-06 CO CONC2021/0016556A patent/CO2021016556A2/es unknown
-
2025
- 2025-03-14 US US19/080,430 patent/US20250243155A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3976581T3 (pl) | Sole kwasu winowego [2-(3-fluoro-5-metanosulfonylofenoksy)etylo](propylo)aminy | |
| IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
| MA40067A (fr) | Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide | |
| IL238535A0 (en) | amine salts of laquinimod | |
| IL312564A (en) | Polymorphs of the hydrochloride salt of linfarezan glurate | |
| FI3993807T3 (fi) | MENETELMÄ LÄÄKETTÄ KÄSITTÄVÄN VESIPITOISEN KOOSTUMUKSEN pH:n STABILOIMISEKSI | |
| AP2015008407A0 (en) | N-(2-(cyclic amine)ethyl) benzamide derivatives asP2X7 inhibitors | |
| HUE063674T2 (hu) | Eljárás N-(amino-imino-metil)-2-aminoetánsav (III) metastabil kristálymódosulatának elõállítására | |
| IL234192B (en) | Crystal forms of 1-(3-tert-butyl-1-p-tolyl-h1-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazole-5-yloxy (benzyl)urea hydrochloride | |
| IL289231A (en) | Salts of compounds, their crystalline forms and their uses | |
| IL290625A (en) | Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use | |
| IL291651A (en) | A new polymorph form of (r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2-methylpropionic acid and its uses. | |
| HUE072877T2 (hu) | Alifás sav-amid származékok | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| ES3062389T3 (en) | Solid state forms of lucerastat salts and process for preparation thereof | |
| IL304836A (en) | Polymorph of leterpyridine dihydrochloride | |
| IL288158A (en) | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| HUE070199T2 (hu) | Izopropilmetilfenol-észter csoportokat tartalmazó amin vegyületek sói, mint vírusellenes, baktériumellenes és antimikotikus szerek | |
| IL290582A (en) | A method for the synthesis of n-converted phenyl-5-hydroxymethyl-2-oxazolidinones | |
| HUE060105T2 (hu) | Eljárás amin-hidroklorid-szuszpenzió elõállítására | |
| GB202113935D0 (en) | Nucleic acid characterisation | |
| HUE064510T2 (hu) | Eljárás N-alkil-hidroxilammónium sókat tartalmazó keverék tisztítására | |
| KR102623532B9 (ko) | 납-금속 화합물 단결정의 개질방법 | |
| HUE067363T2 (hu) | Eljárás elektróda elõállítására akkumulátorhoz | |
| PT3643704T (pt) | Novos intermediários para a preparação de hidrocloreto de remifentanil |